High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions

Endocrine Journal

Volumn 52, Issue 6, 2005, Pages 751-756

  Okinaga, Hiroko ^a   Matsuno, Akira ^b   Okazaki, Ryo ^b  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Bone mineral density; Craniopharyngioma; Hypogonadotropic hypogonadism; Pituitary tumor; Urinary type I collagen N telopeptide

Indexed keywords

GONADOTROPIN; HYDROCORTISONE; SEX HORMONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOPHARYNGIOMA; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MALE; OSTEOPENIA; POSTOPERATIVE PERIOD; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; BONE DENSITY; BONE DISEASES, METABOLIC; BONE RESORPTION; CHILD; COLLAGEN; COLLAGEN TYPE I; CRANIOPHARYNGIOMA; DIPHOSPHONATES; ESTROGENS; FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; HYDROCORTISONE; HYPOPITUITARISM; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PEPTIDES; PITUITARY NEOPLASMS; RALOXIFENE; RISK FACTORS; TESTOSTERONE; THYROXINE;

EID: 30844453395     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.52.751     Document Type: Article

References (14)

1. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM (1994) Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab 78: 669-674.
2. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA (1997) Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 137: 240-245.
3. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81: 4358-4365.
4. Muller HL, Schneider P, Bueb K, Etavard-Gorris N, Gebhardt U, Kolb R, Sorensen N (2003) Volumetric bone mineral density in patients with childhood craniopharyngioma. Exp Clin Endocrinol Diabetes 111: 168-173.
5. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207.
6. Roth C, Wilken B, Hanefeld F, Schroter W, Leonhardt U (1998) Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. Eur J Endocrinol 138: 89-91.
7. Brabant G, Horn R, Mayr B, von Zur Muhlen A, Honegger J, Buchfelder M (1996) Serum leptin levels following hypothalamic surgery. Horm Metab Res 28: 728-731.
8. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxf) 39: 1383-1389.
9. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA (1994) Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 120: 207-210.
10. Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, Weetman AP (1997) Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 46: 255-261.
11. Guo CY, Weetman AP, Eastell R (1997) Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf) 46: 301-307.
12. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A (1994) Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 78: 818-823.
13. Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M (2003) TSH is a negative regulator of skeletal remodeling. Cell 115: 151-162.
14. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89: 2085-2098.